Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Among all mental disorders, major depression has the highest rate of prevalence and incidence of morbidity. Currently available antidepressant therapies have limited efficacies; consequently, research on new drugs for the treatment of mood disorders has become increasingly critical. Recent preclinical evidences that cannabinoid agonists and endocannabinoid enhancers, such as the fatty acid amide hydrolase (FAAH) inhibitors, can impact mood regulation have opened a new line of research in antidepressant drug discovery. However, the neurobiological mechanisms linking the endocannabinoid system with the pathophysiology of mood disorders and antidepressant action remain unclarified. In this review, we have presented an update on preclinical data indicating the antidepressant potential of cannabinoid agonists and endocannabinoid enhancers in comparison to standard antidepressants. Data obtained from CB(1) knockout (CB(1)-/-) and FAAH knockout (FAAH-/-) mice have also been examined within this context. We have illustrated how the various classes of antidepressants exert their therapeutic action. In particular, all antidepressants increase the neurotransmission of serotonin after long-term treatment, enhance the tonic activity of hippocampal 5-HT(1A) receptors, promote neurogenesis, and modulate (decrease or increase) the firing activity of noradrenergic neurons. Interestingly, cannabinoid agonists and endocannabinoid enhancers increase serotonin and noradrenergic neuronal firing activity, increase serotonin release in the hippocampus, as well as promote neurogenesis. Since cannabinoid-derived drugs potentiate monoaminergic neurotransmission and hippocampal neurogenesis through distinct pathways compared to classical antidepressants, they may represent an alternative drug class in the pharmacotherapy of mood and other neuropsychiatric disorders.
Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montréal, Québec, Canada.
Francis Rodriguez
FR
Bambico
Andrea
A
Duranti
Andrea
A
Tontini
Giorgio
G
Tarzia
Gabriella
G
Gobbi
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism; D002186:Cannabinoids / Q000494:pharmacology*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D063388:Endocannabinoids; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D055495:Neurogenesis / Q000187:drug effects; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D012701:Serotonin / Q000378:metabolism
D000928:Antidepressive Agents; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D063388:Endocannabinoids; D043884:Receptor, Cannabinoid, CB1; D012701:Serotonin